NO905201L - Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater.

Info

Publication number
NO905201L
NO905201L NO90905201A NO905201A NO905201L NO 905201 L NO905201 L NO 905201L NO 90905201 A NO90905201 A NO 90905201A NO 905201 A NO905201 A NO 905201A NO 905201 L NO905201 L NO 905201L
Authority
NO
Norway
Prior art keywords
group
alkyl
alkenyl
constitutes
alkoxy
Prior art date
Application number
NO90905201A
Other languages
English (en)
Other versions
NO905201D0 (no
Inventor
Barry Clive Ross
David Middlemiss
David Ian Carter Scopes
Torquil Iain Maclean Jack
Kevin Stuart Cardwell
Michael Dennis Dowle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898929071A external-priority patent/GB8929071D0/en
Priority claimed from GB909011186A external-priority patent/GB9011186D0/en
Priority claimed from GB909019436A external-priority patent/GB9019436D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO905201D0 publication Critical patent/NO905201D0/no
Publication of NO905201L publication Critical patent/NO905201L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives forbindelser med den generelle formel (I). eller et fysiologisk akseptabelt salt, solvat eller en ugiftig metabolsk labil ester derav, hvor1 utgjør et hydrogen- eller halogenatom eller en gruppe valgt fra Calkyl, C.alkenyl, f luorCj-ealkyl, C.alkoksy, -CHO, -O,eller -COR; Ar utgjør gruppenR utgjør en gruppe valgt fra c.alkyl, C.alkenyl, C_alkoksy eller gruppen -NR10Rn;3 utgjør en gruppe valgt fra -C0H, -NHS0CFeller en C-bundet tetirazolylgruppe; Rog Rsom kan være like eller forskjellige, utgjør et hydrogen- eller halogenatom eller en C_alkylgruppe; Het utgjør en N-bundet imidazolylgruppe som i 2-stillingen eventuelt er substituert med en C_alkyl-, C.alkenyl- eller Calkyltiogruppe, hvor imidazolylgruppen eventuelt kan være substituert i 4- og 5-stillingen med én eller to ytterligere substituenter valgt fra et halogenatom eller en gruppe valgt fra cyano, nitro, C.alkyl, C.alkenyl, fluorC^alkyl, -(CH)R, -(CH)„COReller - (CH2) pNRBCOR9 ; Rutgjør en hydroksy- eller Calkoksygruppe;. Rutgjør et hydrogenatom eller en gruppe valgt fra hydroksy, C^alkyl, C^alkoksy, fenyl, fenoksy eller gruppen -NRl0R11 ;. Rs utgjør et hydrogenatom eller en Calkylgruppe; Rutgjør. et hydrogenatom eller en gruppe valgt fra C.alkyl, Calkoksy, fenyl, fenoksy eller gruppen -N101og11 som kan være like eller forskjellige, utgjør uavhengig av hverandre, et hydrogenatom eller en C.alkylgruppe, eller -NRRdanner en mettet heterocyklisk ring som har 5 eller 6 ring-ledd og hvor ringen eventuelt kan inneholde et oksygenatom; m utgjør et heltall fra 1 til 4; n utgjør et heltall fra 0 til'4; og p utgjør et heltall fra 1 til 4.
NO90905201A 1989-12-01 1990-11-30 Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater. NO905201L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB898927277A GB8927277D0 (en) 1989-12-01 1989-12-01 Chemical compounds
GB898929071A GB8929071D0 (en) 1989-12-22 1989-12-22 Chemical compounds
GB909011186A GB9011186D0 (en) 1990-05-18 1990-05-18 Chemical compounds
GB909019436A GB9019436D0 (en) 1990-09-06 1990-09-06 Chemical compounds
OA60008A OA10044A (en) 1989-12-01 1991-05-28 Benzofuran derivatives

Publications (2)

Publication Number Publication Date
NO905201D0 NO905201D0 (no) 1990-11-30
NO905201L true NO905201L (no) 1991-06-03

Family

ID=33314473

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90905201A NO905201L (no) 1989-12-01 1990-11-30 Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater.

Country Status (16)

Country Link
EP (1) EP0434249A3 (no)
JP (1) JPH04217975A (no)
CN (1) CN1052672A (no)
AU (1) AU638077B2 (no)
CA (1) CA2031324A1 (no)
CZ (1) CZ597190A3 (no)
FI (1) FI905908A7 (no)
GB (1) GB8927277D0 (no)
HU (1) HUT61751A (no)
IE (1) IE904333A1 (no)
IL (1) IL96516A0 (no)
NO (1) NO905201L (no)
NZ (1) NZ236297A (no)
OA (1) OA10044A (no)
PL (1) PL288039A1 (no)
PT (1) PT96042A (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093351A (en) * 1989-01-05 1992-03-03 Du Pont Merck Pharmaceutical Company Substituted indole, benzofuran and benzothiophene derivatives as 5-lipoxygenase inhibitors
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
US5177095A (en) * 1990-02-13 1993-01-05 Merck & Co., Inc. Triazole angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
GB9026006D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
IL100917A0 (en) * 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
WO1992016552A1 (en) * 1991-03-25 1992-10-01 Glaxo Group Limited 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5252574A (en) * 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
JPH06211845A (ja) * 1991-05-16 1994-08-02 Glaxo Group Ltd ベンゾフラン誘導体
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110623D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
WO1992020679A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Benzofuran derivatives
GB9113628D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
TW300219B (no) * 1991-09-14 1997-03-11 Hoechst Ag
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane
US5225408A (en) * 1991-12-20 1993-07-06 E. R. Squibb & Sons, Inc. Biphenyl oxadiazinone angiotensin II inhibitors
US5364869A (en) * 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
ES2135472T3 (es) * 1992-04-13 1999-11-01 Zeneca Ltd Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.
US5294722A (en) * 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
GB9217723D0 (en) * 1992-08-20 1992-09-30 Ici Plc Chemical process
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB2279346A (en) * 1993-07-01 1995-01-04 Glaxo Group Ltd Benzofuran intermediates
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DE10154313A1 (de) 2001-11-05 2003-05-15 Bayer Cropscience Ag Halogen-nitro-butadiene
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
US20250051315A1 (en) * 2021-12-28 2025-02-13 Alchemedicine, Inc. Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118552A (en) * 1982-04-15 1983-11-02 Pfizer Ltd Thromboxane synthetase inhibitors
US4452986A (en) * 1982-06-08 1984-06-05 The Upjohn Company Imidazolyl-substituted benzofurans
DE3876006T2 (de) * 1987-04-14 1993-03-25 Glaxo Group Ltd Keton-derivate.
EP0445073A1 (de) * 1990-02-27 1991-09-04 Ciba-Geigy Ag Benzofurane

Also Published As

Publication number Publication date
HUT61751A (en) 1993-03-01
PT96042A (pt) 1991-09-13
GB8927277D0 (en) 1990-01-31
NZ236297A (en) 1992-10-28
AU6763290A (en) 1991-06-06
PL288039A1 (en) 1991-08-12
CZ597190A3 (en) 1995-02-15
EP0434249A2 (en) 1991-06-26
EP0434249A3 (en) 1992-02-12
CA2031324A1 (en) 1991-06-02
OA10044A (en) 1996-10-14
CN1052672A (zh) 1991-07-03
IE904333A1 (en) 1991-06-05
FI905908A7 (fi) 1991-06-02
AU638077B2 (en) 1993-06-17
FI905908A0 (fi) 1990-11-30
HU908016D0 (en) 1991-06-28
JPH04217975A (ja) 1992-08-07
NO905201D0 (no) 1990-11-30
IL96516A0 (en) 1991-08-16

Similar Documents

Publication Publication Date Title
NO905201L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzofuran-derivater.
YU48105B (sh) Derivati triazola i postupak za njihovo dobijanje
EA200500910A1 (ru) Бифенильные производные и их применение в качестве фунгицидов
ES479021A1 (es) Procedimiento para preparar composiones insecticidas y aca- ricidas a base de derivados sustituidos de fenoxibenciloxi- carbonilo.
DE69304057D1 (de) Indole fungizide
NO20064297L (no) Aminoalkoholforbindelse
EA200000400A1 (ru) Галогензамещенные тетрациклические производные тетрагидрофурана
NO156787B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
DK225081A (da) Aminopropiophenon-derivater og deres syreadditionssalte fremgangsmaader til deres fremstilling og deres anvendelse som gungicider
NO912298D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksanderivater.
ATE238297T1 (de) Chinolinderivat
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
ES450166A1 (es) Procedimiento de preparacion de nuevos derivados de amino- benzociclohepteno.
CA2014521A1 (en) 2-Substituted N,N'-Ditrimethoxybenzoyl Piperazines, a Preparation Process of the Same and Therapeutic Compositions Containing Them
DK224981A (da) Aminopropanol-derivater og deres syreadditionssalte fremgangsmaader til deres fremstilling og deres anvendelse som fungicider
IL66705A (en) Hetero-substituted pyrid-4-one derivatives,their preparation and their use as herbicides
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
SE8007025L (sv) Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem
DK455285A (da) 2-pyridin-thiolderivater
NO885224L (no) Fremgangsmaate for fremstilling av 1,4-disubstituerte-piperidinylderivater.
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
FR2840304B1 (fr) Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
ATE19629T1 (de) N-substituierte derivate des tetrahydroisophthalimids.
JPS53111035A (en) Phenylthiourea derivatives and insecticides containing the same as active ingredient